ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD-8835. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2022-08-24

Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen.

Varga A, Márton É, Markovics A, Penyige A, Balogh I, Nagy B, Szilágyi M.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines10092060

Bibliografisk träff 2022-04-24

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells.

Piazzi M, Bavelloni A, Cenni V, Salucci S, Bartoletti Stella A, Tomassini E, Scotlandi K, Blalock WL, Faenza I.

Molecules · research-article; journal article · DOI 10.3390/molecules27092742

Bibliografisk träff 2020-03-03

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.

Wu YH, Huang YF, Chen CC, Huang CY, Chou CY.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.00206

Bibliografisk träff 2019-04-01

Screening of PI3K-Akt-targeting Drugs for Silkworm against Bombyx mori Nucleopolyhedrovirus.

Wang B, Jiang L, Guo H, Sun Q, Wang Y, Xie E, Xia Q.

Molecules · research-article; journal article · DOI 10.3390/molecules24071260

Bibliografisk träff 2019-01-16

AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.

Wang Y, Chen X, Chen X, Zhou Z, Xu W, Xu F, Zhang S.

J Cell Physiol · research support, non-u.s. gov't; journal article · DOI 10.1002/jcp.27711

Bibliografisk träff 2018-12-27

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.

Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, Crafter C, Sidders B, Hardaker E, Hudson K, Barry ST.

J Immunother Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s40425-018-0457-0

Bibliografisk träff 2018-04-20

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.

Avivar-Valderas A, McEwen R, Taheri-Ghahfarokhi A, Carnevalli LS, Hardaker EL, Maresca M, Hudson K, Harrington EA, Cruzalegui F.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.25118

Bibliografisk träff 2017-08-14

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

Maynard J, Emmas SA, Ble FX, Barjat H, Lawrie E, Hancox U, Polanska UM, Pritchard A, Hudson K.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0183048

Bibliografisk träff 2017-02-15

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood · journal article · DOI 10.1182/blood-2016-12-758599

Bibliografisk träff 2016-04-01

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.8031

Bibliografisk träff 2016-02-02

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Hudson K, Hancox UJ, Trigwell C, McEwen R, Polanska UM, Nikolaou M, Morentin Gutierrez P, Avivar-Valderas A, Delpuech O, Dudley P, Hanson L, Ellston R, Jones A, Cumberbatch M, Cosulich SC, Ward L, Cruzalegui F, Green S.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-15-0687

Bibliografisk träff 2015-10-09

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.

Barlaam B, Cosulich S, Delouvrié B, Ellston R, Fitzek M, Germain H, Green S, Hancox U, Harris CS, Hudson K, Lambert-van der Brempt C, Lebraud H, Magnien F, Lamorlette M, Le Griffon A, Morgentin R, Ouvry G, Page K, Pasquet G, Polanska U, Ruston L, Saleh T, Vautier M, Ward L.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2015.10.002

Gå till forskningen.

Publikationer i urvalet

Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen.

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells.

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.

Screening of PI3K-Akt-targeting Drugs for Silkworm against <i>Bombyx mori</i> Nucleopolyhedrovirus.

AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8<sup>+</sup> T-cell activity.

Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancer.

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.